# PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

> **NCT00548093** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 66 (actual)

## Conditions studied

- Carcinoma, Non Small Cell Lung

## Interventions

- **DRUG:** PF-00299804
- **DRUG:** PF-00299804

## Key facts

- **NCT ID:** NCT00548093
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-29
- **Primary completion:** 2010-03-16
- **Final completion:** 2012-06-11
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548093, "PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00548093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*